Xenon Pharmaceuticals Inc. 8-K

What Happened Xenon Pharmaceuticals Inc. (NASDAQ: XENE) filed a Form 8‑K on May 7, 2026 to announce its financial results for the three months ended March 31, 2026. The company issued a press release with those results, which is attached to the 8‑K as Exhibit 99.1 (the exhibit is furnished, not filed).

Key Details

• Press release dated May 7, 2026 reporting quarterly results for the period ended March 31, 2026 (Exhibit 99.1).
• Exhibit 99.1 is furnished to the SEC under Item 2.02 (Results of Operations and Financial Condition).
• Under Regulation FD disclosure (Item 7.01), Xenon confirms it communicates material information via SEC filings, press releases, public calls, its corporate and investor websites, and social media (X/@XenonPharma, LinkedIn, Facebook).
• The Form 8‑K was signed by Thomas P. Kelly, Chief Financial Officer, on May 7, 2026.

Why It Matters The press release contains Xenon’s quarterly financial metrics and is the primary source for investors to assess the company’s recent performance (earnings, revenue, cash position, and any operational updates). Because Xenon uses multiple public channels to disclose material information, investors should review the attached press release on the company’s investor site or the SEC EDGAR filing to get the full, definitive financial details.